Home › Kanser (lahat ng uri) › South Dakota
Pag-aaral pangklinika para sa Kanser (lahat ng uri) sa South Dakota
13 pag-aaral para sa Kanser (lahat ng uri) ang naghahanap ng mga kalahok sa mga site sa South Dakota.
Mga Lungsod sa South Dakota
Opisyal na teksto ng pag-aaral (English)
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
- Sanford Children's Hospital ( Site 4015), Sioux Falls
Nagre-recruitPhase 1/2
1 Month – 17 Years · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07630974TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Sanford Cancer Center Oncology Clinic and Pharmacy, Sioux Falls
Nagre-recruitPhase 2
Edad 12 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT02693535Connect for Cancer Prevention Study (Connect)
- Sanford Health, Sioux Falls
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 30 hanggang 70 · Lahat ng kasarian · Na-update Set 17, 2026 · NCT04609072A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
- Sanford Children's Hospital ( Site 3015), Sioux Falls
Nagre-recruitPhase 1/2
1 Month – 17 Years · Lahat ng kasarian · Na-update Set 17, 2026 · NCT06941272A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Sioux Falls
Nagre-recruitPhase 3
Edad 18 hanggang 130 · Lahat ng kasarian · Na-update Set 8, 2026 · NCT07647328A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
- Sanford Sioux Falls, Sioux Falls
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Set 3, 2026 · NCT06163534KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
- Sanford Cancer Center Oncology Clinic ( Site 0038), Sioux Falls
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT07252739Project: Every Child for Younger Patients With Cancer
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Nagre-recruitObservasyonal na pag-aaral
Hanggang edad 25 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT02402244Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Avera Cancer Institute-Aberdeen, Aberdeen
- Avera Cancer Institute - Mitchell, Mitchell
- Avera Cancer Institute at Pierre, Pierre
- at 4 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 7, 2026 · NCT06580314Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
- Avera Medical Group Gynecologic Oncology Sioux Falls, Sioux Falls
- Texas Oncology, P.A. - Tyler, Sioux Falls
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Hul 28, 2026 · NCT07022483I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Sanford Clinical Research, Sioux Falls
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update May 6, 2026 · NCT01042379Avera Cancer Sequencing and Analytics Protocol (ASAP)
- Avera Cancer Institute - Aberdeen, Aberdeen
- Avera Cancer Institute - Mitchell, Mitchell
- Avera Cancer Institute - Pierre, Pierre
- at 2 pa
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 27, 2026 · NCT05142033Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 27, 2024 · NCT03860883Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.